Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Cardlytics Inc (NASDAQ: CDLX) closed the day trading at $1.64 down -1.20% from the previous closing price of $1.66. In other words, the price has decreased by -$1.20% from its previous closing price. On the day, 0.75 million shares were traded. CDLX stock price reached its highest trading level at $1.775 during the session, while it also had its lowest trading level at $1.63.
Ratios:
For a better understanding of CDLX, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.65 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 84.41. For the most recent quarter (mrq), Quick Ratio is recorded 1.19 and its Current Ratio is at 1.19. In the meantime, Its Debt-to-Equity ratio is 3.44 whereas as Long-Term Debt/Eq ratio is at 2.70.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Evercore ISI on October 11, 2024, initiated with a In-line rating and assigned the stock a target price of $4.
On August 16, 2024, Northland Capital Downgraded its rating to Market Perform which previously was Outperform but kept the price unchanged to $5.
BofA Securities Downgraded its Neutral to Underperform on August 15, 2024, whereas the target price for the stock was revised from $4 to $3.50.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 15 ’25 when DeSieno Alexis sold 26,217 shares for $1.94 per share. The transaction valued at 50,809 led to the insider holds 164,833 shares of the business.
DeSieno Alexis bought 26,217 shares of CDLX for $50,809 on May 15 ’25. On Apr 22 ’25, another insider, Lynton Nicholas Hollmeyer, who serves as the Chief Legal & Privacy Officer of the company, sold 303 shares for $1.51 each. As a result, the insider received 458 and left with 102,119 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDLX now has a Market Capitalization of 86103936 and an Enterprise Value of 254783920. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.32 while its Price-to-Book (P/B) ratio in mrq is 1.34. Its current Enterprise Value per Revenue stands at 0.935 whereas that against EBITDA is -6.344.
Stock Price History:
The Beta on a monthly basis for CDLX is 1.25, which has changed by -0.79702973 over the last 52 weeks, in comparison to a change of 0.11213791 over the same period for the S&P500. Over the past 52 weeks, CDLX has reached a high of $9.48, while it has fallen to a 52-week low of $1.22. The 50-Day Moving Average of the stock is -6.99%, while the 200-Day Moving Average is calculated to be -43.38%.
Shares Statistics:
Over the past 3-months, CDLX traded about 877.26K shares per day on average, while over the past 10 days, CDLX traded about 978500 shares per day. A total of 52.17M shares are outstanding, with a floating share count of 49.80M. Insiders hold about 5.16% of the company’s shares, while institutions hold 54.72% stake in the company. Shares short for CDLX as of 1748563200 were 8571256 with a Short Ratio of 9.77, compared to 1745971200 on 8367572. Therefore, it implies a Short% of Shares Outstanding of 8571256 and a Short% of Float of 19.07.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Cardlytics Inc (CDLX) is the result of assessments by 4.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.01 and low estimates of -$0.16.
Analysts are recommending an EPS of between -$0.26 and -$0.65 for the fiscal current year, implying an average EPS of -$0.49. EPS for the following year is -$0.53, with 2.0 analysts recommending between -$0.53 and -$0.53.
Revenue Estimates
5 analysts predict $64.06M in revenue for the current quarter. It ranges from a high estimate of $64.77M to a low estimate of $63.31M. As of the current estimate, Cardlytics Inc’s year-ago sales were $69.64MFor the next quarter, 5 analysts are estimating revenue of $68.21M. There is a high estimate of $70.3M for the next quarter, whereas the lowest estimate is $66.28M.
A total of 6 analysts have provided revenue estimates for CDLX’s current fiscal year. The highest revenue estimate was $275.75M, while the lowest revenue estimate was $259.8M, resulting in an average revenue estimate of $270.55M. In the same quarter a year ago, actual revenue was $278.3MBased on 5 analysts’ estimates, the company’s revenue will be $287.04M in the next fiscal year. The high estimate is $306.09M and the low estimate is $269.9M.
